Insulin Resistance and Atherogenic Dyslipidemia Drive Cardiac Remodeling and Cardiovascular Events After Kidney

Ioana Adela Ratiu1,2, Cristina Mihaela Brisc1, Alina Daciana Elec3

  • 1Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 1st December Square 10, 410073 Oradea, Romania.

Insights

Metabolic abnormalities, not inflammation, are linked to cardiac remodeling in kidney transplant recipients. Simple metabolic indices like TyG and AIP can help stratify cardiovascular risk post-transplant.

Area of Science:

  • Nephrology and Transplant Medicine
  • Cardiovascular Medicine
  • Metabolic and Endocrine Disorders

Background:

  • Cardiovascular disease (CVD) is a major cause of death and illness after kidney transplantation.
  • The roles of metabolic issues and inflammation in cardiac changes and outcomes post-transplant are not fully understood.

Purpose of the Study:

  • To investigate the association between metabolic abnormalities, inflammation, and cardiac remodeling in kidney transplant recipients (KTRs).
  • To determine the predictive value of metabolic indices and inflammation for adverse clinical outcomes after kidney transplantation.

Main Methods:

  • Retrospective cohort study of 152 KTRs evaluated 12 months post-transplant.
  • Metabolic phenotype assessed via metabolic syndrome, insulin resistance (TyG index), and atherogenic dyslipidemia (TG/HDL ratio, AIP).
  • Inflammatory status evaluated using hs-CRP and CBC-derived indices; cardiac remodeling defined by echocardiographic damage composite (EDC).

Main Results:

  • Over half of KTRs (51.3%) had EDC, strongly associated with metabolic indices (TyG, AIP, TG/HDL) but not inflammation.
  • TyG and AIP independently predicted EDC, irrespective of inflammation (hs-CRP).
  • Metabolic indices (TyG, AIP) predicted major adverse cardiovascular and cerebrovascular events (MACCE), while inflammation and graft dysfunction predicted major adverse clinical outcomes (MACO).

Conclusions:

  • Metabolic abnormalities, particularly insulin resistance and atherogenic dyslipidemia, are linked to cardiac remodeling and cardiovascular events in KTRs.
  • Systemic inflammation and graft dysfunction are key predictors of overall adverse clinical outcomes.
  • TyG index and AIP offer practical tools for cardiovascular risk stratification in KTRs.

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
827
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
32
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
926
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K